Viking Therapeutics, Inc.
GB ˙ LSE ˙ US92686J1060
29,87 $ ↑0,55 (1,88%)
2026-06-04
DEL PRIS
SecurityGB:0VQA / Viking Therapeutics, Inc.
InstitutionIMC-Chicago, LLC
Latest Disclosed Ownership31,426 shares
Latest Disclosed Value $ 1,022,602
IMC-Chicago, LLC ownership in 0VQA / Viking Therapeutics, Inc.

On May 5, 2026 - IMC-Chicago, LLC filed a 13F-HR form disclosing ownership of 31,426 shares of Viking Therapeutics, Inc. (GB:0VQA) valued at $1,024,488 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 17,513 shares of Viking Therapeutics, Inc.. This represents a change in shares of 79.44% during the quarter. The current value of the position is $938,695 USD.

IMC-Chicago, LLC has a history of taking positions in derivatives of the underlying security (0VQA) in the form of stock options. The firm currently holds call options representing 298,500 of underlying shares valued at $9,713,190 USD and put options representing 104,400 of underlying shares valued at $3,397,176 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

GB:0VQA / Viking Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 31,426 13,913 79.44 1,023 65.91 0.0004
2026-01-29 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 17,513 -2,598 -12.92 616 16.67 0.0002
2025-11-04 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 20,111 -287 -1.41 529 -2.22 0.0002
2025-07-22 2025-06-30 13F VIKING THERAPEUTICS COM 92686J106 20,398 20,398 541 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F VIKING THERAPEUTICS COM Call 298,500 -8.46 9,713 -15.33 n/a n/a n/a
2026-01-29 2025-12-31 13F VIKING THERAPEUTICS COM Call 326,100 -6.29 11,472 25.45 n/a n/a n/a
2025-11-04 2025-09-30 13F VIKING THERAPEUTICS COM Call 348,000 225.23 9,145 222.57 n/a n/a n/a
2025-07-22 2025-06-30 13F VIKING THERAPEUTICS COM Call 107,000 2,836 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F VIKING THERAPEUTICS COM Put 104,400 30.34 3,397 20.59 n/a n/a n/a
2026-01-29 2025-12-31 13F VIKING THERAPEUTICS COM Put 80,100 -32.23 2,818 -9.30 n/a n/a n/a
2025-11-04 2025-09-30 13F VIKING THERAPEUTICS COM Put 118,200 130.86 3,106 129.06 n/a n/a n/a
2025-07-22 2025-06-30 13F VIKING THERAPEUTICS COM Put 51,200 1,357 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.